Multiple Firms Seek Lead Role in Gossamer Bio Securities Suit After PROSERA Miss

Overview

• Gossamer disclosed in February 2026 that its Phase 3 PROSERA trial missed the preplanned primary six‑minute‑walk endpoint and the stock plunged, prompting shareholder complaints.
• Plaintiffs allege the company hid specific failures to control an outsized placebo response at Latin American sites and other trial‑design or monitoring flaws that they say drove the negative outcome.
• Several plaintiff‑side firms have filed complaints and are actively soliciting investors who bought Gossamer securities between June 16, 2025 and February 20, 2026 to move for lead‑plaintiff status by the June 1, 2026 deadline.
• No class has been certified, no liability or damages have been found, and the litigation remains at an early procedural stage in which a court will decide who leads the case.
• The suits raise potential consequences for investors and the company, including claims for investor losses, possible damages recoveries if plaintiffs prevail, and unresolved listing or market impacts tied to the trial disclosure.